4.7 Review

von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends

期刊

BLOOD
卷 125, 期 13, 页码 2019-2028

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2014-06-528406

关键词

-

资金

  1. Agence Nationale de la Recherche [ANR-13-BSV1-0014]
  2. Agence Nationale de la Recherche (ANR) [ANR-13-BSV1-0014] Funding Source: Agence Nationale de la Recherche (ANR)

向作者/读者索取更多资源

To understand the placement of a certain protein in a physiological system and the pathogenesis of related disorders, it is not only of interest to determine its function but also important to describe the sequential steps in its life cycle, from synthesis to secretion and ultimately its clearance. von Willebrand factor (VWF) is a particularly intriguing case in this regard because of its important auxiliary roles (both intra-and extracellular) that implicate a wide range of other proteins: its presence is required for the formation and regulated release of endothelial storage organelles, the Weibel-Paladebodies(WPBs), whereas VWF is also a key determinant in the clearance of coagulation factor VIII. Thus, understanding the molecular and cellular basis of the VWF life cycle will help us gain insight into the pathogenesis of von Willebrand disease, design alternative treatment options to prolong the factor VIII half-life, and delineate the role of VWF and coresidents of the WPBs in the prothrombotic and proinflammatory response of endothelial cells. In this review, an update on our current knowledge on VWF biosynthesis, secretion, and clearance is provided and we will discuss how they can be affected by the presence of protein defects.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor

Elena Barbon, Charlotte Kawecki, Solenne Marmier, Aboud Sakkal, Fanny Collaud, Severine Charles, Giuseppe Ronzitti, Caterina Casari, Olivier D. Christophe, Cecile V. Denis, Peter J. Lenting, Federico Mingozzi

Summary: Von Willebrand disease (VWD), the most common inherited bleeding disorder, has limited efficacy with current liver-directed gene therapy. This study developed a gene therapy strategy using an optimized AAV vector and endothelial-targeting peptide to deliver the VWF gene into endothelial cells, achieving long-term expression.

GENE THERAPY (2023)

Article Hematology

Gain-of-Function Variant p.Pro2555Arg of von Willebrand Factor Increases Aggregate Size through Altering Stem Dynamics

Volker Huck, Po-Chia Chen, Emma-Ruoqi Xu, Alexander Tischer, Ulrike Klemm, Camilo Aponte-Santamaria, Christian Mess, Tobias Obser, Fabian Kutzki, Gesa Koenig, Cecile V. Denis, Frauke Graeter, Matthias Wilmanns, Matthew Auton, Stefan W. Schneider, Reinhard Schneppenheim, Janosch Hennig, Maria A. Brehm

Summary: This study uncovered a prothrombotic gain of function associated with a VWF variant located in the C4 domain, leading to an increase in platelet aggregate size and affecting the structural flexibility. The research highlights the uniqueness of this VWF variant and its significance for vascular health.

THROMBOSIS AND HAEMOSTASIS (2022)

Article Cardiac & Cardiovascular Systems

The VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells

Jeremy Lagrange, Morel E. Worou, Jean-Baptiste Michel, Alexandre Raoul, Melusine Didelot, Vincent Muczynski, Paulette Legendre, Francois Plenat, Guillaume Gauchotte, Marc-Damien Lourenco-Rodrigues, Olivier D. Christophe, Peter J. Lenting, Patrick Lacolley, Cecile Denis, Veronique Regnault

Summary: VWF induces VSMC proliferation through A2 domain binding to LRP4 receptor and integrin alpha(v)beta(3) signaling. These findings provide new insights into the mechanisms that drive physiological repair and pathological hyperplasia of the arterial vessel wall.

CARDIOVASCULAR RESEARCH (2022)

Article Hematology

A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD

Claire Kizlik-Masson, Ivan Peyron, Stephane Gangnard, Gaelle Le Goff, Solen M. Lenoir, Sandra Damodaran, Marie Clavel, Stephanie Roullet, Veronique Regnault, Antoine Rauch, Flavien Vincent, Emmanuelle Jeanpierre, Annabelle Dupont, Catherine Ternisien, Thibault Donnet, Olivier D. Christophe, Eric van Belle, Cecile Denis, Caterina Casari, Sophie Susen, Peter J. Lenting

Summary: A nanobody (KB-VWF-D3.1) is identified to distinguish proteolyzed and non-proteolyzed VWF and monitor VWF degradation levels. Reduced intact-VWF levels are observed in patients with von Willebrand disease, aortic stenosis, and patients receiving mechanical circulatory support.
Meeting Abstract Hematology

A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a

Vincent Muczynski, Angel Smith, Thibaud Sefiane, Olivier D. Christophe, Peter J. Lenting, David Granger, Kerry Chester, Amit C. Nathwani

Article Hematology

Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models

Stephanie Roullet, Norman Luc, Julie Rayes, Jean Solarz, Dante Disharoon, Andrew Ditto, Emily Gahagan, Christa Pawlowski, Thibaud Sefiane, Frederic Adam, Caterina Casari, Olivier D. Christophe, Michael Bruckman, Peter J. Lenting, Anirban Sen Gupta, Cecile Denis

Summary: The lack of innovation in von Willebrand disease (VWD) is due to the complexity and heterogeneity of the disease and a lack of recognition of the impact of bleeding symptoms experienced by patients. This study proposes a new approach using synthetic platelet (SP) nanoparticles for the treatment of VWD-2B and severe VWD. The results show that SP can improve thrombus formation and reduce blood loss in VWD-2B and VWF-KO mice.
Article Cardiac & Cardiovascular Systems

Shear Forces Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia

Antoine Rauch, Annabelle Dupont, Mickael Rosa, Maximilien Desvages, Christina Le Tanno, Johan Abdoul, Melusine Didelot, Alexandre Ung, Richard Ruez, Emmanuelle Jeanpierre, Melanie Daniel, Delphine Corseaux, Hugues Spillemaeker, Julien Labreuche, Benedicte Pradines, Natacha Rousse, Peter J. Lenting, Mouhamed D. Moussa, Andre Vincentelli, Jean-Claude Bordet, Bart Staels, Flavien Vincent, Cecile V. Denis, Eric Van Belle, Caterina Casari, Sophie Susen

Summary: Thrombocytopenia is consistently observed in ECMO patients, with a time-dependent decrease in platelet count, GP Ib alpha shedding, and increased soluble GP Ib alpha levels. Shedding of GP Ib alpha is dependent on rheological conditions, with higher rates at high-flow speeds.

CIRCULATION RESEARCH (2023)

Article Hematology

Angiopoietin-2 binds to multiple interactive sites within von Willebrand factor

Alexis Texier, Peter J. Lenting, Cecile Denis, Stephanie Roullet, Olivier D. Christophe

Summary: This study reveals the binding between von Willebrand factor and angiopoietin-2, with angiopoietin-2 enhancing the binding of von Willebrand factor to angiopoietin-1.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

MAGT1 deficiency in XMEN disease is associated with severe platelet dysfunction and impaired platelet glycoprotein N-glycosylation

Alexandre Kauskot, Coralie Mallebranche, Arnaud Bruneel, Francois Fenaille, Jean Solarz, Toscane Viellard, Miao Feng, Christelle Reperant, Jean-Claude Bordet, Sophie Cholet, Cecile Denis, Genevieve McCluskey, Sylvain Latour, Emmanuel Martin, Isabelle Pellier, Dominique Lasne, Delphine Borgel, Sven Kracker, Alban Ziegler, Marie Tuffigo, Benjamin Fournier, Charline Miot, Frederic Adam

Summary: XMEN disease, caused by loss-of-function mutations in the MAGT1 gene, is associated with platelet dysfunction and defective N-glycosylation, which may explain the bleeding events in patients with XMEN disease.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab

Melissa Bou-Jaoudeh, Angelina Mimoun, Sandrine Delignat, Ivan Peyron, Ladislas Capdevila, Victoria Daventure, Claire Deligne, Jordan D. Dimitrov, Olivier D. Christophe, Cecile V. Denis, Peter J. Lenting, Valerie Proulle, Sebastien Lacroix-Desmazes

Summary: This study investigated the impact of IdeS treatment in inhibitor-positive HA mice injected with emicizumab. The results showed that IdeS efficiently eliminated anti-FVIII IgG and restored the hemostatic efficacy of exogenous FVIII, unaffected by the presence of emicizumab and polyclonal human IgG in the mice.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Review Hematology

Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress

Robert A. Ariens, Beverley J. Hunt, Ejaife O. Agbani, Josefin Ahnstrom, Robert Ahrends, Raza Alikhan, Alice Assinger, Zsuzsa Bagoly, Alessandra Balduini, Elena Barbon, Christopher D. Barrett, Paul Batty, Jorge David Aivazoglou Carneiro, Wee Shian Chan, Moniek de Maat, Kerstin de Wit, Cecile Denis, Martin H. Ellis, Renee Eslick, Hongxia Fu, Catherine P. M. Hayward, Benoit Ho-Tin-Noe, Frederikus A. Klok, Riten Kumar, Karin Leiderman, Rustem I. Litvinov, Nigel Mackman, Zoe McQuilten, Matthew D. Neal, William A. E. Parker, Roger J. S. Preston, Julie Rayes, Alireza R. Rezaie, Lara N. Roberts, Bianca Rocca, Susan Shapiro, Deborah M. Siegal, Lirlandia P. Sousa, Katsue Suzuki-Inoue, Tahira Zafar, Jiaxi Zhou

Summary: The ISTH London 2022 Congress is the first face-to-face conference since the COVID-19 pandemic. The conference proceedings are also streamed online for those unable to attend. The scientific program covers a wide range of topics and the Illustrated Review article is a revolutionary way to communicate research.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

Article Hematology

Identification of von Willebrand factor D4 domain mutations in patients of Afro-Caribbean descent: In vitro characterization

Marie-Daniela Dubois, Ivan Peyron, Olivier-Nicolas Pierre-Louis, Serge Pierre-Louis, Johalene Rabout, Pierre Boisseau, Annika de Jong, Sophie Susen, Jenny Goudemand, Remi Neviere, Pascal Fuseau, Olivier D. Christophe, Peter J. Lenting, Cecile Denis, Caterina Casari

Summary: This study reports two mutations in the D4 domain of VWF that induce combined qualitative and quantitative defects. One mutation leads to almost complete intracellular retention of the protein, while the other mutation results in reduced binding to collagen and platelet receptors.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

Article Hematology

New insights into regulation of αIIbβ3 integrin signaling by filamin A

Lamia Lamrani, Frederic Adam, Christelle Soukaseum, Cecile Denis, Hana Raslova, Jean-Philippe Rosa, Marijke Bryckaert

Summary: This study evaluates the role of filamin A (FLNa) subdomains in regulating integrin alpha IIb beta 3 signaling. The results show that FLNa-actin and FLNa-beta 3 interactions negatively regulate alpha IIb beta 3 activation, while FLNa dimerization domain negatively regulates alpha IIb beta 3 outside-in signaling.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

暂无数据